---
layout: default
title: Carboplatin
description: "Carboplatin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 40
evidence_level: L1
indication_count: 10
---

# Carboplatin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Carboplatinï¼šå¾åŒ–ç™‚åŸºçŸ³åˆ°å¥³æ€§ä¹³è…ºç™Œçš„æ–°æ¢ç´¢

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Carboplatin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Carboplatin æ˜¯é‰‘é¡æŠ—ç™Œè—¥ç‰©ï¼Œå·²å»£æ³›ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰è¶…é **50 å€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | HER2 é™½æ€§æ—©æœŸä¹³ç™Œã€è½‰ç§»æ€§ä¹³ç™Œã€é»‘è‰²ç´ ç˜¤ã€éå°ç´°èƒè‚ºç™Œã€ä½•æ°é‡‘æ°æ·‹å·´ç˜¤ã€é ­é ¸éƒ¨é±—ç‹€ç´°èƒç™Œã€æ³Œå°¿é“ä¸Šçš®ç™Œç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€primary non-gestational choriocarcinoma of ovaryã€hereditary breast ovarian cancer syndromeã€ovarian clear cell adenocarcinomaã€ovarian mucinous adenocarcinomaã€yolk sac tumorã€maligant granulosa cell tumor of ovaryã€ovarian endometrioid adenocarcinomaã€rectum mucinous adenocarcinomaã€colon mucinous adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.86% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ï¼ˆç‚ºå¤šç¨®è¤‡æ–¹æ²»ç™‚çš„ä¸€éƒ¨åˆ†ï¼‰ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µï¼ˆä½œç‚º Trastuzumabã€Pembrolizumab ç­‰è—¥ç‰©é©æ‡‰ç—‡çš„ä½µç”¨è—¥ç‰©ï¼‰ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.86%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Carboplatin æ˜¯ä¸€ç¨®é‰‘é¡æŠ—ç™Œè—¥ç‰©ï¼Œé€éèˆ‡ DNA å½¢æˆäº¤å‰é€£çµä¾†æŠ‘åˆ¶è…«ç˜¤ç´°èƒå¢æ®–ã€‚å…¶ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š</p>

<ol>
<li><strong>DNA æå‚·æ©Ÿåˆ¶</strong>ï¼šCarboplatin èˆ‡ DNA å½¢æˆé‰‘-DNA åŠ åˆç‰©ï¼Œå¹²æ“¾ DNA è¤‡è£½èˆ‡è½‰éŒ„</li>
<li><strong>ç´°èƒé€±æœŸé˜»æ»¯</strong>ï¼šèª˜å°ç´°èƒé€±æœŸåœæ»¯ï¼Œä¿ƒé€²è…«ç˜¤ç´°èƒå‡‹äº¡</li>
<li><strong>å°ä¸‰é™°æ€§ä¹³è…ºç™Œçš„ç‰¹æ®Šç™‚æ•ˆ</strong>ï¼šç ”ç©¶é¡¯ç¤º carboplatin å° BRCA çªè®Šç›¸é—œçš„ä¸‰é™°æ€§ä¹³è…ºç™Œå…·æœ‰è‰¯å¥½ç™‚æ•ˆ</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>äººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT06027268">NCT06027268</a></td>
<td>Phase 2</td>
<td>ACTIVE_NOT_RECRUITING</td>
<td>36</td>
<td>è©•ä¼° trilaciclibã€pembrolizumabã€gemcitabine å’Œ carboplatin åœ¨è½‰ç§»æ€§ä¸‰é™°æ€§ä¹³è…ºç™Œä¸­çš„ç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00047255">NCT00047255</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>263</td>
<td>æ¯”è¼ƒ docetaxel/trastuzumab èˆ‡ docetaxel/carboplatin/trastuzumab åœ¨ HER2 é™½æ€§è½‰ç§»æ€§ä¹³è…ºç™Œçš„ç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT01881230">NCT01881230</a></td>
<td>Phase 2/3</td>
<td>COMPLETED</td>
<td>191</td>
<td>è©•ä¼° nab-paclitaxel èˆ‡ gemcitabine æˆ– carboplatin åœ¨ä¸‰é™°æ€§è½‰ç§»æ€§ä¹³è…ºç™Œçš„ç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT02413320">NCT02413320</a></td>
<td>Phase 2</td>
<td>COMPLETED</td>
<td>101</td>
<td>è©•ä¼°å« carboplatin åŒ–ç™‚æ–¹æ¡ˆåœ¨ä¸‰é™°æ€§ä¹³è…ºç™Œæ–°è¼”åŠ©æ²»ç™‚ä¸­çš„ç—…ç†å®Œå…¨ç·©è§£ç‡</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT01445418">NCT01445418</a></td>
<td>Phase 1</td>
<td>COMPLETED</td>
<td>103</td>
<td>ç ”ç©¶ PARP æŠ‘åˆ¶åŠ‘ AZD2281 èˆ‡ carboplatin ä½µç”¨åœ¨ BRCA1/2 çªè®Šæ”œå¸¶è€…ä¹³è…ºç™Œä¸­çš„å®‰å…¨æ€§</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>Carboplatin åœ¨ä¹³è…ºç™Œæ²»ç™‚ä¸­çš„æ‡‰ç”¨å·²æœ‰å¤šé …ç ”ç©¶æ”¯æŒï¼Œå°¤å…¶åœ¨ä»¥ä¸‹é ˜åŸŸï¼š</p>

<ol>
<li><strong>ä¸‰é™°æ€§ä¹³è…ºç™Œ (TNBC)</strong>ï¼šå¤šé …è‡¨åºŠè©¦é©—é¡¯ç¤º carboplatin å¯æé«˜ TNBC çš„ç—…ç†å®Œå…¨ç·©è§£ç‡</li>
<li><strong>BRCA çªè®Šç›¸é—œä¹³è…ºç™Œ</strong>ï¼šcarboplatin å° DNA ä¿®å¾©ç¼ºé™·çš„è…«ç˜¤ç´°èƒå…·æœ‰è¼ƒé«˜æ•æ„Ÿæ€§</li>
<li><strong>HER2 é™½æ€§ä¹³è…ºç™Œ</strong>ï¼šèˆ‡ trastuzumab ä½µç”¨å·²è¢«è­‰å¯¦æœ‰æ•ˆ</li>
</ol>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. rectum mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.28%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. colon mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.26%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ7 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21794003/" target="_blank">21794003</a></td><td>2011</td><td>Article</td><td>The journal of obste</td><td>Metastatic urachal carcinoma of the ovary.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33298341/" target="_blank">33298341</a></td><td>2021</td><td>Article</td><td>European journal of </td><td>Laparoscopic cytoreductive surgery and hyperthermic intraper...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15852675/" target="_blank">15852675</a></td><td>2005</td><td>Article</td><td>Hinyokika kiyo. Acta</td><td>[Carcinoma of the urachus: a case report].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29927186/" target="_blank">29927186</a></td><td>2016</td><td>Article</td><td>Journal of the Medic</td><td>Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11420638/" target="_blank">11420638</a></td><td>2001</td><td>Article</td><td>Gene therapy</td><td>Intravenous infusion of a replication-selective adenovirus (...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 2 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. adult germ cell tumor</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01445119" target="_blank">NCT01445119</a></td><td>PHASE1</td><td>COMPLETED</td><td>58</td><td>A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00293358" target="_blank">NCT00293358</a></td><td>PHASE3</td><td>COMPLETED</td><td>500</td><td>SIOP Intracranial Germ Cell Tumours Protocol</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00010036" target="_blank">NCT00010036</a></td><td>PHASE2</td><td>COMPLETED</td><td>N/A</td><td>A Phase I/II Trial of CPT-11 With Carboplatin in Patients With Glioblastoma Mult...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00536601" target="_blank">NCT00536601</a></td><td>NA</td><td>COMPLETED</td><td>174</td><td>Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Sel...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01857453" target="_blank">NCT01857453</a></td><td>PHASE2</td><td>UNKNOWN</td><td>97</td><td>National, Multicentric, Prospective Phase II Study Estimating the Interest of a ...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01652794" target="_blank">NCT01652794</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Bod...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06870565" target="_blank">NCT06870565</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>238</td><td>A Multicenter Randomized Study Comparing Paclitaxel and Platinum-based Concurren...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. gallbladder mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.23%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. endometrial mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ3 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01652794" target="_blank">NCT01652794</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Bod...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01081262" target="_blank">NCT01081262</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>50</td><td>A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Pacl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01440998" target="_blank">NCT01440998</a></td><td>PHASE1</td><td>COMPLETED</td><td>18</td><td>Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplat...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34092768/" target="_blank">34092768</a></td><td>2021</td><td>Article</td><td>Journal of UOEH</td><td>Synchronous Occurrence of Ovarian Seromucinous Carcinoma and...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19473054/" target="_blank">19473054</a></td><td>2009</td><td>Article</td><td>Neoplasma</td><td>Gemcitabine and carboplatin treatment in patients with relap...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30718314/" target="_blank">30718314</a></td><td>2019</td><td>Article</td><td>International journa</td><td>Adenosine triphosphate-based chemotherapy response assay pre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16884360/" target="_blank">16884360</a></td><td>2006</td><td>Article</td><td>International journa</td><td>Interferon-gamma in combination with carboplatin and paclita...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26763061/" target="_blank">26763061</a></td><td>2015</td><td>Article</td><td>Annals of the Academ</td><td>Singapore Cancer Network (SCAN) Guidelines for the Systemic ...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. endometrial mixed adenocarcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ4 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05252416" target="_blank">NCT05252416</a></td><td>PHASE1</td><td>TERMINATED</td><td>50</td><td>A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03914612" target="_blank">NCT03914612</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>813</td><td>A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05542407" target="_blank">NCT05542407</a></td><td>PHASE1</td><td>RECRUITING</td><td>58</td><td>Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05256225" target="_blank">NCT05256225</a></td><td>PHASE3</td><td>RECRUITING</td><td>360</td><td>A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Tra...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ10 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25611899/" target="_blank">25611899</a></td><td>2015</td><td>Article</td><td>International journa</td><td>Carboplatin and nonpegylated liposomal doxorubicin in primar...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19890461/" target="_blank">19890461</a></td><td>2006</td><td>Article</td><td>American journal of </td><td>Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tum...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10811505/" target="_blank">10811505</a></td><td>2000</td><td>Article</td><td>Annals of oncology :</td><td>Endometrial mesodermal mixed tumor occurring after tamoxifen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31993743/" target="_blank">31993743</a></td><td>2020</td><td>Article</td><td>Journal of cancer re</td><td>Should MMMT still be treated with adjuvant taxane-based comb...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14599858/" target="_blank">14599858</a></td><td>2003</td><td>Article</td><td>Gynecologic oncology</td><td>A phase II trial of three sequential doublets for the treatm...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 5 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. villoglandular endometrial endometrioid adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. extrahepatic bile duct mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.18%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027591è™Ÿ | æ›²æ–¯è‹¥å‡æ™¶æ³¨å°„åŠ‘150æ¯«å…‹ | å‡æ™¶æ³¨å°„åŠ‘ | èˆ‡ docetaxel åŠ carboplatin ä½µç”¨ä¹‹ HER2 é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©ç™‚æ³• |
| è¡›ç½²è—¥è¼¸å­—ç¬¬027591è™Ÿ | è³€ç™Œå¹³çš®ä¸‹æ³¨å°„åŠ‘ | çš®ä¸‹æ³¨å°„åŠ‘ | èˆ‡ docetaxel åŠ carboplatin ä½µç”¨ä¹‹ HER2 é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©ç™‚æ³• |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028264è™Ÿ | å‰èˆ’é”è†œè¡£éŒ  | è†œè¡£éŒ  | èˆ‡ pemetrexed åŠ carboplatin ä½µç”¨ä¹‹è½‰ç§»æ€§éé±—ç‹€éå°ç´°èƒè‚ºç™Œç¬¬ä¸€ç·šæ²»ç™‚ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰© |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜åº¦ï¼ˆè¡€å°æ¿æ¸›å°‘ç‚ºåŠ‘é‡é™åˆ¶æ¯’æ€§ï¼‰ |
| è‡´åæ€§åˆ†ç´š | ä¸­åº¦è‡³é«˜åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è…åŠŸèƒ½ï¼ˆè‚Œé…¸é…æ¸…é™¤ç‡ï¼‰ã€é›»è§£è³ª |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

**é‡è¦è­¦èª**ï¼š
- Carboplatin ä¸»è¦ç¶“è…è‡Ÿæ’æ³„ï¼Œè…åŠŸèƒ½ä¸å…¨æ‚£è€…éœ€èª¿æ•´åŠ‘é‡
- éª¨é«“æŠ‘åˆ¶ç‚ºä¸»è¦æ¯’æ€§ï¼Œéœ€å®šæœŸç›£æ¸¬è¡€çƒè¨ˆæ•¸
- å¯èƒ½å¼•èµ·éæ•åæ‡‰ï¼Œå°¤å…¶æ˜¯å¤šæ¬¡ä½¿ç”¨å¾Œ

**è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
- èˆ‡å…¶ä»–éª¨é«“æŠ‘åˆ¶è—¥ç‰©ä½µç”¨å¯èƒ½å¢åŠ è¡€æ¶²æ¯’æ€§
- èˆ‡è…æ¯’æ€§è—¥ç‰©ï¼ˆå¦‚ aminoglycoside æŠ—ç”Ÿç´ ï¼‰ä½µç”¨éœ€è¬¹æ…
- é¿å…èˆ‡æ´»æ€§ç–«è‹—åŒæ™‚ä½¿ç”¨

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šè‘¡è„æŸšå°é‰‘é¡åŒ–ç™‚è—¥å½±éŸ¿è¼ƒå°
- å»ºè­°ï¼šç„¡éœ€ç‰¹åˆ¥é™åˆ¶


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Peripheral Nervous System Diseases** ğŸ”´ Major
- æ³¨æ„äº‹é …ï¼šMild peripheral neuropathy has been noted during carboplatin therapy and is characterized most frequently by paresthesias...

**Infections** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€æ„ŸæŸ“ã€‚

**Hemorrhagic Disorders** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€å‡ºè¡€ã€è¡€æ “ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€å‡ºè¡€ã€æ„ŸæŸ“ã€è¡€æ “ã€è²§è¡€ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Carboplatin åœ¨ä¹³è…ºç™Œæ²»ç™‚ä¸­å·²æœ‰å¤§é‡è‡¨åºŠè©¦é©—è­‰æ“šæ”¯æŒï¼Œå°¤å…¶åœ¨ä¸‰é™°æ€§ä¹³è…ºç™Œå’Œ BRCA çªè®Šç›¸é—œä¹³è…ºç™Œä¸­é¡¯ç¤ºè‰¯å¥½ç™‚æ•ˆã€‚å¤šé … Phase 2/3 è©¦é©—å·²å®Œæˆæˆ–æ­£åœ¨é€²è¡Œä¸­ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å¯†åˆ‡ç›£æ¸¬éª¨é«“æŠ‘åˆ¶å’Œè…åŠŸèƒ½
- é‡å°ç‰¹å®šåˆ†å­äºå‹ï¼ˆå¦‚ BRCA çªè®Šã€ä¸‰é™°æ€§ï¼‰çš„å€‹é«”åŒ–ç”¨è—¥ç­–ç•¥
- èˆ‡è…«ç˜¤ç§‘åœ˜éšŠå¯†åˆ‡åˆä½œï¼Œåˆ¶å®šé©ç•¶çš„ä½µç”¨æ–¹æ¡ˆ

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Dronedarone]({{ "/drugs/dronedarone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Carboplatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/carboplatin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_carboplatin,
  title = {Carboplatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/carboplatin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
